However, two-sample KS and MWU tests both indicated that, at the 5% significance level, there were statistically significant differences in the distribution of the the tumor control, nivolumab-treated, and pembrolizumab-treated average Ki-67 isotype expression (p-values: 0.0109, 0.0346, 0.0015 (KS); 0.0147, 0.0233, 0.0018 (MWU), respectively) and the control and nivolumab-treated average IFNγ expression (p-values: 0.0080, 0.0015 (KS); 0.0102, 0.0041 (MWU), respectively), see Fig. 5. The gene discussed is MKI67; the disease is neoplasm.